IFF attributes the Scent rebound to significantly strengthened R&D capability and pipeline, alongside improved go-to-market execution and resilient Fragrance Ingredients amid Middle East volatility. In H2, Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance should normalize to low single digits; sustained R&D investment backs the 2027 growth plan.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
The Scent segment recovery is being supported by (a) progress in R&D capability and pipeline, (b) commercial execution and market-share rebuilding, (c) better management of Fine Fragrance volatility tied to the Middle East, and (d) strength in Fragrance Ingredients, including a mix shift back toward higher-value components over time.
Management describes that ~2.5 years ago the Scent R&D pipeline “was not what it should have been,” but now IFF believes it has a “very strong R&D capability,” with “a great pipeline of molecules as well as delivery systems” and “leading-edge new Fine Fragrances and Consumer Fragrances.” 1 This is explicitly positioned as a core lever for strengthening Scent’s competitive position into the future. 1
On the Consumer Fragrance side, management links the rebuild of R&D capability together with a rebuild of the go-to-market approach with customers to “drive market share gains.” 2
Fine Fragrance was pressured by uncertainty/volatility from the Middle East, but management reports the team “managed that uncertainty” and Fine Fragrance finished “up slightly positive” versus an expected “down… mid-single digits” coming into Q2. 3 The recovery cadence is described as: “softer Q3” (partly due to a difficult year-over-year comparison) and then “recovery… as we get to Q4.” 3 Management also highlights a large Q3 comp: “year-over-year in Q3 last year, Fine Fragrance grew 20%,” which helps explain why the second half is not uniform. 3
Fragrance Ingredients drove a major portion of Scent’s Q2 performance: Scent sales were up 8%, with Fragrance Ingredients growing “north of 20%,” helped in part by difficult comps (“comparing to a down 10% or more in the year ago period”). 3 Importantly, management expects normalization: growth in Fragrance Ingredients will “shift back towards… higher value-added ingredients versus… traditional synthetics,” and management notes that this normalization will take more time and is not expected to be the dominant theme in the second half, but rather “as we go into next year and the year after.” 2
Management provided directional growth-rate expectations for the second half, separately for Fine Fragrance and Consumer Fragrance, plus an outlook note on Fragrance Ingredients.
Although the question asks about Fine and Consumer Fragrance, management explicitly distinguishes Fragrance Ingredients because it is a key part of the overall “Scent” recovery story:
The excerpts provide both qualitative and directional specifics about how R&D is expected to underpin the trajectory into 2027.
Management says IFF has moved from an underperforming pipeline “2.5 years ago” to today’s “very strong R&D capability,” with “leading-edge” perfumers developing new Fine and Consumer fragrances and a “great pipeline of molecules as well as delivery systems.” 1 This is presented as the structural basis for optimism about “the future of Scent.” 1
On Consumer Fragrance, management explicitly states the team is rebuilding not just R&D capability but also the go-to-market approach with customers to “drive market share gains.” 2 Since market-share gains typically require repeatable innovation plus customer acceptance, this coupling is effectively the R&D execution plan supporting the 2027 competitive position. 2
While the question is about 2027 support, the excerpts emphasize that some ingredient/value shifts take time:
Management also quantifies the ongoing investment emphasis indirectly: IFF is reinvesting at an R&D intensity “in that 8% to 9% range,” described as “really important that we critically continue to reinvest… because it becomes that circle where we make those investments, we get the better growth rate and ultimately allows us to… continue to reinvest.” 4 This reinforces that R&D is expected to remain a sustained support mechanism leading into later years rather than a short-term fix. 4
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent recovery is driven by a rebuilt R&D pipeline and improved go-to-market execution, with Fragrance Ingredients strength supporting near-term momentum. The 2H outlook assigns modest growth for Fine Fragrance and low-single-digit gains for Consumer Fragrance, while the R&D plan aims to sustain competitive positioning and growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF highlights three reinforcing drivers for Scent’s recovery—strong commercial execution, an enhanced R&D capability, and normalization of prior-period comparables—while Fine Fragrance navigates a softer Q3 with a stronger Q4, and Consumer Fragrance benefits from a rebuilt R&D and go-to-market strategy. The plan for 2027 centers on a strengthened R&D pipeline and delivery systems to sustain competitiveness, with Fragrance Ingredients expected to normalize after a high Q2 and gradually shift toward higher-value natural products.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Post-divestiture, IFF plans Capex around 5-6% of sales, with the upper end near 6% in the next 1-2 years to fund high-return initiatives, while keeping reinvestment and R&D at 8-9% of sales to support growth. Near-term cash-flow timing headwinds from the divestiture are expected, but full-year 2026 free cash flow should exceed 2025.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is anchored in a rebuilt R&D engine and stronger go-to-market execution, with near-term tailwinds from fragrance ingredients. 2H 2026 guidance shows Fine Fragrance accelerating into Q4 while Consumer Fragrance normalizes to low single-digit growth, as Middle East volatility subsides. The 2027 plan focuses on a robust pipeline and higher-value ingredient mix to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to a rebuilt R&D engine, stronger perfumers, and improved go-to-market execution, while guiding a softer Q3 and stronger Q4 for Fine Fragrance and a normalized low single-digit path for Consumer Fragrance in 2H. The company also emphasizes an expanded R&D program—molecules, delivery systems, and higher-value ingredients—to sustain growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi